2018
Obesity and risk for venous thromboembolism from contemporary therapy for pediatric acute lymphoblastic leukemia
Prasca S, Carmona R, Ji L, Ko R, Bhojwani D, Rawlins Y, Mittelman S, Young G, Orgel E. Obesity and risk for venous thromboembolism from contemporary therapy for pediatric acute lymphoblastic leukemia. Thrombosis Research 2018, 165: 44-50. PMID: 29567586, PMCID: PMC7522001, DOI: 10.1016/j.thromres.2018.02.150.Peer-Reviewed Original ResearchConceptsDual-energy X-ray absorptiometryAcute lymphoblastic leukemiaSymptomatic venous thromboembolismVenous thromboembolismLymphoblastic leukemiaDevelopment of venous thromboembolismPediatric acute lymphoblastic leukemiaAcute lymphoblastic leukemia therapyRetrospective cohort of childrenX-ray absorptiometryLong-term morbiditySubgroup of patientsVenous thromboembolism riskRisk-stratified approachMeasures of body fatCohort of childrenALL cohortStudy-definedRetrospective cohortVTE riskContemporary therapyIncreased riskBody compositionBody fatObesity
2017
Predictors of hepatotoxicity and pancreatitis in children and adolescents with acute lymphoblastic leukemia treated according to contemporary regimens
Denton C, Rawlins Y, Oberley M, Bhojwani D, Orgel E. Predictors of hepatotoxicity and pancreatitis in children and adolescents with acute lymphoblastic leukemia treated according to contemporary regimens. Pediatric Blood & Cancer 2017, 65 PMID: 29218844, PMCID: PMC7522002, DOI: 10.1002/pbc.26891.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAge FactorsAntineoplastic Combined Chemotherapy ProtocolsChemical and Drug Induced Liver InjuryChildChild, PreschoolCohort StudiesDisease-Free SurvivalFemaleHumansIncidenceInfantMaleObesityPancreatitisPrecursor Cell Lymphoblastic Leukemia-LymphomaRetrospective StudiesRisk FactorsYoung AdultConceptsEvent-free survivalAcute lymphoblastic leukemiaPredictors of hepatotoxicityChildren's Oncology GroupLymphoblastic leukemiaClinically significant pancreatitisCases of pancreatitisContemporary treatment regimensIdentification of patientsTreatment risk factorsDose interruptionEOI-MRDOncology GroupPrimary endpointSecondary endpointsALL cohortChemotherapy interruptionStudy-definedTreatment regimensCumulative incidencePancreatitisToxicity surveillanceToxicity criteriaRisk factorsRegimens